Advanced BioMatrix acquires HyStem from Lineage Cell Therapeutics
HyStem kits are based on innovative thiolated hyaluronic acid technology. With
HyStem kits are based on innovative thiolated hyaluronic acid technology. With
The acquisition follows LGC’s recent acquisition of Toronto Research Chemicals
Acquisition adds platform in gene variant interpretation based on next generation sequencing
New grading system promises opportunities for the re-use of old batteries instead of disposing or recycling them
Cell line to be used to support research and development of biotherapeutics across therapeutic areas
Carbon nanotube film produces aerospace-grade composites with no need for huge ovens or autoclaves
New cell treatment could help maintain healthy blood sugar levels
Single Technologies aims to deliver a paradigm shift in biomolecular analysis with Theta platform
Collaboration aims to develop the next-generation of engineered CHO cell lines and improve production of biotherapeutics
Waters enables core product portfolio with next-generation automation technology
Web-based platform provides access to one of the first ever cloud laboratory to integrate automated biology and chemistry research capabilities
This enhanced partnership promises to deliver end-to-end genomic solutions for plant research and development
This collaboration promises to develop stem cell therapies for life-threatening diseases
Major learned societies initiate two-year strategic alliance
This technology was showcased at the 2019 ASH Annual Meeting
Joint venture to develop next generation cell and gene therapies incorporating Affimer proteins
The molecule points the way toward treating viruses that cross from animals to humans